English

HALOZYME THERAPEUTICS, INC.

EDGAR

HALO Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 1.397B, using the latest reported figures. The previous period, 2024, was about USD 1.015B.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

481 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 480999000 USD Source

Operating margin

59.8%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 287654000 USD Source
Revenue: 480999000 USD Source

Operating cash flow

241 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 420969000 USD Source
Operating Cash Flow: 180078000 USD Source

Free cash flow

237 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 420969000 USD Source
Operating Cash Flow: 180078000 USD Source
Capital Expenditure: 7914000 USD Source
Capital Expenditure: 3741000 USD Source

Cash and cash equivalents: 163 million USD 2026-06-30 Source
Exact value

163138000 USD
Long-term debt including current maturities: 2.14 billion USD 2025-12-31 Source
Exact value

2142630000 USD
Shares outstanding: 114 million shares 2026-06-30 Source
Exact value

114042000 shares

Reported share-count change

-3.04% · -3.58 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

117621000 shares · 2025-06-30· Source
114042000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.66 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 354264000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 1396611000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 944844000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 376708000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 480999000 USD · 2026-04-01 – 2026-06-30 Source

Net income

414 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: 175225000 USD · 2025-07-01 – 2025-09-30 Source
Net income: 316889000 USD · 2025-01-01 – 2025-12-31 Source
Net income: 458480000 USD · 2025-01-01 – 2025-09-30 Source
Net income: 150049000 USD · 2026-01-01 – 2026-03-31 Source
Net income: 229913000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

819 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 432529000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 253932000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 651558000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 432529000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 180078000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 420969000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 180078000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

12.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 5543000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2513000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 6970000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 5543000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3741000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 7914000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3741000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

806 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 432529000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 253932000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 651558000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 432529000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 180078000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 420969000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 180078000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5543000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2513000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 6970000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 5543000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3741000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 7914000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3741000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 11 of 11 periods available· newest 2025-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+37.6%

Prior period

USD 1.02 billion

2024-01-01 – 2024-12-31
Current period

USD 1.4 billion

2025-01-01 – 2025-12-31

Exact inputs and evidence

1396611000 − 1015324000 = 381287000 USD

1015324000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1396611000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Year-over-year change in Revenue: 381287000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1396611000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1804216 Filing: 000115903626000024 Input fundies:Revenue: 1015324000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1805211 Filing: 000115903626000024
The citation records this snapshot. The page link may show a newer release later.
Net income
-28.6%

Prior period

USD 444.09 million

2024-01-01 – 2024-12-31
Current period

USD 316.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

316889000 − 444091000 = -127202000 USD

444091000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
316889000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Year-over-year change in Net income: -127202000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 316889000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#2266288 Filing: 000115903626000024 Input fundies:NetIncome: 444091000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#2266958 Filing: 000115903626000024
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+36%

Prior period

USD 479.06 million

2024-01-01 – 2024-12-31
Current period

USD 651.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

651558000 − 479064000 = 172494000 USD

479064000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
651558000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Year-over-year change in Operating cash flow: 172494000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 651558000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1272704 Filing: 000115903626000024 Input fundies:OperatingCashFlow: 479064000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1273357 Filing: 000115903626000024
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-34.8%

Prior period

USD 10.7 million

2024-01-01 – 2024-12-31
Current period

USD 6.97 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

6970000 − 10696000 = -3726000 USD

10696000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
6970000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Year-over-year change in Capital expenditure: -3726000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6970000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284130 Filing: 000115903626000024 Input fundies:CapitalExpenditure: 10696000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284719 Filing: 000115903626000024
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 1.4 billion 100% of revenue
Operating costs Derived USD 927.61 million 66% of revenue
Operating income USD 469.01 million 34% of revenue
Tax, interest and other Derived USD 152.12 million 11% of revenue
Net income USD 316.89 million 23% of revenue

Cash

Operating cash flow USD 651.56 million 47% of revenue
Capital expenditure USD 6.97 million 0.5% of revenue
Free cash flow Derived USD 644.59 million 46% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 157% of revenue.
2017 20%74%
2018 Operating loss: operating costs were 146% of revenue.
2019 Operating loss: operating costs were 134% of revenue.
2020 48%46%
2021 Net income was higher than operating income, so the split is not drawn.
2022 31%9.9%59%
2023 34%59%
2024 44%11%46%
2025 23%11%66%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	146691000	229901000 Derived	-83210000	19813000 Derived	-103023000	-53520000 Derived	Source 2016-01-01 – 2016-12-31: 146691000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -83210000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -103023000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -50383000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3137000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	316613000	235611000 Derived	81002000	18031000 Derived	62971000	132703000 Derived	Source 2017-01-01 – 2017-12-31: 316613000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 81002000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 62971000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 134053000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1350000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	151862000	221192000 Derived	-69330000	11000000 Derived	-80330000	-54163000 Derived	Source 2018-01-01 – 2018-12-31: 151862000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -69330000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -80330000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -49500000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 4663000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	195992000	263602000 Derived	-67610000	4630000 Derived	-72240000	-89463000 Derived	Source 2019-01-01 – 2019-12-31: 195992000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -67610000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -72240000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -85423000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 4040000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	267594000	123339000 Derived	144255000	15170000 Derived	129085000	52950000 Derived	Source 2020-01-01 – 2020-12-31: 267594000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 144255000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 129085000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 55454000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2504000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	443310000	167408000 Derived	275902000	-126808000 Derived	402710000	297983000 Derived	Source 2021-01-01 – 2021-12-31: 443310000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 275902000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 402710000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 299440000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1457000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	660116000	392585000 Derived	267531000	65402000 Derived	202129000	235300000 Derived	Source 2022-01-01 – 2022-12-31: 660116000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 267531000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 202129000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 240110000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 4810000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	829253000	491679000 Derived	337574000	55980000 Derived	281594000	373277000 Derived	Source 2023-01-01 – 2023-12-31: 829253000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: 337574000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 281594000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 388571000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 15294000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1015324000	463849000 Derived	551475000	107384000 Derived	444091000	468368000 Derived	Source 2024-01-01 – 2024-12-31: 1015324000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: 551475000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 444091000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 479064000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 10696000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1396611000	927605000 Derived	469006000	152117000 Derived	316889000	644588000 Derived	Source 2025-01-01 – 2025-12-31: 1396611000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: 469006000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 316889000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 651558000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 6970000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.4B 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	146691000	Revenue: 146691000 Open source
20172017-12-31	Revenue	316613000	Revenue: 316613000 Open source
20182018-12-31	Revenue	151862000	Revenue: 151862000 Open source
20192019-12-31	Revenue	195992000	Revenue: 195992000 Open source
20202020-12-31	Revenue	267594000	Revenue: 267594000 Open source
20212021-12-31	Revenue	443310000	Revenue: 443310000 Open source
20222022-12-31	Revenue	660116000	Revenue: 660116000 Open source
20232023-12-31	Revenue	829253000	Revenue: 829253000 Open source
20242024-12-31	Revenue	1015324000	Revenue: 1015324000 Open source
20252025-12-31	Revenue	1396611000	Revenue: 1396611000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

37.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	8.6%	Revenue: 146691000 Open source Revenue: 135057000 Open source
20172017-12-31	Year over year	115.8%	Revenue: 316613000 Open source Revenue: 146691000 Open source
20182018-12-31	Year over year	-52%	Revenue: 151862000 Open source Revenue: 316613000 Open source
20192019-12-31	Year over year	29.1%	Revenue: 195992000 Open source Revenue: 151862000 Open source
20202020-12-31	Year over year	36.5%	Revenue: 267594000 Open source Revenue: 195992000 Open source
20212021-12-31	Year over year	65.7%	Revenue: 443310000 Open source Revenue: 267594000 Open source
20222022-12-31	Year over year	48.9%	Revenue: 660116000 Open source Revenue: 443310000 Open source
20232023-12-31	Year over year	25.6%	Revenue: 829253000 Open source Revenue: 660116000 Open source
20242024-12-31	Year over year	22.4%	Revenue: 1015324000 Open source Revenue: 829253000 Open source
20252025-12-31	Year over year	37.6%	Revenue: 1396611000 Open source Revenue: 1015324000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 33.6% 2025

Net margin 22.7% 2025

Free cash flow margin 46.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-56.7%	Operating Income: -83210000 Open source Revenue: 146691000 Open source
20172017-12-31	Operating margin	25.6%	Operating Income: 81002000 Open source Revenue: 316613000 Open source
20182018-12-31	Operating margin	-45.7%	Operating Income: -69330000 Open source Revenue: 151862000 Open source
20192019-12-31	Operating margin	-34.5%	Operating Income: -67610000 Open source Revenue: 195992000 Open source
20202020-12-31	Operating margin	53.9%	Operating Income: 144255000 Open source Revenue: 267594000 Open source
20212021-12-31	Operating margin	62.2%	Operating Income: 275902000 Open source Revenue: 443310000 Open source
20222022-12-31	Operating margin	40.5%	Operating Income: 267531000 Open source Revenue: 660116000 Open source
20232023-12-31	Operating margin	40.7%	Operating Income: 337574000 Open source Revenue: 829253000 Open source
20242024-12-31	Operating margin	54.3%	Operating Income: 551475000 Open source Revenue: 1015324000 Open source
20252025-12-31	Operating margin	33.6%	Operating Income: 469006000 Open source Revenue: 1396611000 Open source
20162016-12-31	Net margin	-70.2%	Net Income: -103023000 Open source Revenue: 146691000 Open source
20172017-12-31	Net margin	19.9%	Net Income: 62971000 Open source Revenue: 316613000 Open source
20182018-12-31	Net margin	-52.9%	Net Income: -80330000 Open source Revenue: 151862000 Open source
20192019-12-31	Net margin	-36.9%	Net Income: -72240000 Open source Revenue: 195992000 Open source
20202020-12-31	Net margin	48.2%	Net Income: 129085000 Open source Revenue: 267594000 Open source
20212021-12-31	Net margin	90.8%	Net Income: 402710000 Open source Revenue: 443310000 Open source
20222022-12-31	Net margin	30.6%	Net Income: 202129000 Open source Revenue: 660116000 Open source
20232023-12-31	Net margin	34%	Net Income: 281594000 Open source Revenue: 829253000 Open source
20242024-12-31	Net margin	43.7%	Net Income: 444091000 Open source Revenue: 1015324000 Open source
20252025-12-31	Net margin	22.7%	Net Income: 316889000 Open source Revenue: 1396611000 Open source
20162016-12-31	Free cash flow margin	-36.5%	Revenue: 146691000 Open source Operating Cash Flow: -50383000 Open source Capital Expenditure: 3137000 Open source
20172017-12-31	Free cash flow margin	41.9%	Revenue: 316613000 Open source Operating Cash Flow: 134053000 Open source Capital Expenditure: 1350000 Open source
20182018-12-31	Free cash flow margin	-35.7%	Revenue: 151862000 Open source Operating Cash Flow: -49500000 Open source Capital Expenditure: 4663000 Open source
20192019-12-31	Free cash flow margin	-45.6%	Revenue: 195992000 Open source Operating Cash Flow: -85423000 Open source Capital Expenditure: 4040000 Open source
20202020-12-31	Free cash flow margin	19.8%	Revenue: 267594000 Open source Operating Cash Flow: 55454000 Open source Capital Expenditure: 2504000 Open source
20212021-12-31	Free cash flow margin	67.2%	Revenue: 443310000 Open source Operating Cash Flow: 299440000 Open source Capital Expenditure: 1457000 Open source
20222022-12-31	Free cash flow margin	35.6%	Revenue: 660116000 Open source Operating Cash Flow: 240110000 Open source Capital Expenditure: 4810000 Open source
20232023-12-31	Free cash flow margin	45%	Revenue: 829253000 Open source Operating Cash Flow: 388571000 Open source Capital Expenditure: 15294000 Open source
20242024-12-31	Free cash flow margin	46.1%	Revenue: 1015324000 Open source Operating Cash Flow: 479064000 Open source Capital Expenditure: 10696000 Open source
20252025-12-31	Free cash flow margin	46.2%	Revenue: 1396611000 Open source Operating Cash Flow: 651558000 Open source Capital Expenditure: 6970000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 651.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-50383000	Operating Cash Flow: -50383000 Open source
20172017-12-31	Operating cash flow	134053000	Operating Cash Flow: 134053000 Open source
20182018-12-31	Operating cash flow	-49500000	Operating Cash Flow: -49500000 Open source
20192019-12-31	Operating cash flow	-85423000	Operating Cash Flow: -85423000 Open source
20202020-12-31	Operating cash flow	55454000	Operating Cash Flow: 55454000 Open source
20212021-12-31	Operating cash flow	299440000	Operating Cash Flow: 299440000 Open source
20222022-12-31	Operating cash flow	240110000	Operating Cash Flow: 240110000 Open source
20232023-12-31	Operating cash flow	388571000	Operating Cash Flow: 388571000 Open source
20242024-12-31	Operating cash flow	479064000	Operating Cash Flow: 479064000 Open source
20252025-12-31	Operating cash flow	651558000	Operating Cash Flow: 651558000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 644.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-53520000	Operating Cash Flow: -50383000 Open source Capital Expenditure: 3137000 Open source
20172017-12-31	Free cash flow	132703000	Operating Cash Flow: 134053000 Open source Capital Expenditure: 1350000 Open source
20182018-12-31	Free cash flow	-54163000	Operating Cash Flow: -49500000 Open source Capital Expenditure: 4663000 Open source
20192019-12-31	Free cash flow	-89463000	Operating Cash Flow: -85423000 Open source Capital Expenditure: 4040000 Open source
20202020-12-31	Free cash flow	52950000	Operating Cash Flow: 55454000 Open source Capital Expenditure: 2504000 Open source
20212021-12-31	Free cash flow	297983000	Operating Cash Flow: 299440000 Open source Capital Expenditure: 1457000 Open source
20222022-12-31	Free cash flow	235300000	Operating Cash Flow: 240110000 Open source Capital Expenditure: 4810000 Open source
20232023-12-31	Free cash flow	373277000	Operating Cash Flow: 388571000 Open source Capital Expenditure: 15294000 Open source
20242024-12-31	Free cash flow	468368000	Operating Cash Flow: 479064000 Open source Capital Expenditure: 10696000 Open source
20252025-12-31	Free cash flow	644588000	Operating Cash Flow: 651558000 Open source Capital Expenditure: 6970000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

98.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	Total Assets: 261515000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 519945000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 440248000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 565874000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 579924000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 1104429000 Open source
20222022-12-31	Liabilities / assets	90.8%	Total Liabilities: 1671713000 Open source Total Assets: 1841511000 Open source
20232023-12-31	Liabilities / assets	95.2%	Total Liabilities: 1649462000 Open source Total Assets: 1733270000 Open source
20242024-12-31	Liabilities / assets	82.4%	Total Liabilities: 1699656000 Open source Total Assets: 2063477000 Open source
20252025-12-31	Liabilities / assets	98.1%	Total Liabilities: 2476509000 Open source Total Assets: 2525323000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.66× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	4.7×	Current Assets: 256532000 Open source Current Liabilities: 54585000 Open source
20172017-12-31	Current assets / current liabilities	3.89×	Current Assets: 510372000 Open source Current Liabilities: 131328000 Open source
20182018-12-31	Current assets / current liabilities	2.86×	Current Assets: 427849000 Open source Current Liabilities: 149361000 Open source
20192019-12-31	Current assets / current liabilities	6.35×	Current Assets: 543436000 Open source Current Liabilities: 85637000 Open source
20202020-12-31	Current assets / current liabilities	1.32×	Current Assets: 554764000 Open source Current Liabilities: 421385000 Open source
20212021-12-31	Current assets / current liabilities	7.91×	Current Assets: 926287000 Open source Current Liabilities: 117147000 Open source
20222022-12-31	Current assets / current liabilities	5.65×	Current Assets: 739013000 Open source Current Liabilities: 130789000 Open source
20232023-12-31	Current assets / current liabilities	6.64×	Current Assets: 746424000 Open source Current Liabilities: 112494000 Open source
20242024-12-31	Current assets / current liabilities	7.8×	Current Assets: 1085340000 Open source Current Liabilities: 139100000 Open source
20252025-12-31	Current assets / current liabilities	4.66×	Current Assets: 825207000 Open source Current Liabilities: 177092000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 103.02 million Exact value Exact value: -103023000 USD 2016-01-01 – 2016-12-31: -103023000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2016-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: -103023000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -103023000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/halo-20181231.xml#281787 Filing: 000115903619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 50.38 million Exact value Exact value: -50383000 USD 2016-01-01 – 2016-12-31: -50383000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2016-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: -50383000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50383000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/halo-20181231.xml#281031 Filing: 000115903619000006 The citation records this snapshot. The page link may show a newer release later.	USD 3.14 million Exact value Exact value: 3137000 USD 2016-01-01 – 2016-12-31: 3137000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2016-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 3137000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3137000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/halo-20181231.xml#300677 Filing: 000115903619000006 The citation records this snapshot. The page link may show a newer release later.	−USD 53.52 million Calculation and evidence -50383000 − 3137000 USD Exact free cash flow: -53520000 USD 2016-01-01 – 2016-12-31: -50383000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3137000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2016-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: -53520000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50383000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/halo-20181231.xml#281031 Filing: 000115903619000006 Input fundies:CapitalExpenditure: 3137000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/halo-20181231.xml#300677 Filing: 000115903619000006 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 62.97 million Exact value Exact value: 62971000 USD 2017-01-01 – 2017-12-31: 62971000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2017-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 62971000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 62971000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/halo2019-10k.htm#1631123 Filing: 000115903620000013 The citation records this snapshot. The page link may show a newer release later.	USD 134.05 million Exact value Exact value: 134053000 USD 2017-01-01 – 2017-12-31: 134053000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2017-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 134053000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 134053000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/halo2019-10k.htm#1279749 Filing: 000115903620000013 The citation records this snapshot. The page link may show a newer release later.	USD 1.35 million Exact value Exact value: 1350000 USD 2017-01-01 – 2017-12-31: 1350000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2017-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 1350000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1350000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/halo2019-10k.htm#1290673 Filing: 000115903620000013 The citation records this snapshot. The page link may show a newer release later.	USD 132.7 million Calculation and evidence 134053000 − 1350000 USD Exact free cash flow: 132703000 USD 2017-01-01 – 2017-12-31: 134053000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1350000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2017-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 132703000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 134053000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/halo2019-10k.htm#1279749 Filing: 000115903620000013 Input fundies:CapitalExpenditure: 1350000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/halo2019-10k.htm#1290673 Filing: 000115903620000013 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 80.33 million Exact value Exact value: -80330000 USD 2018-01-01 – 2018-12-31: -80330000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2018-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: -80330000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80330000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/halo-20201231.htm#1449228 Filing: 000115903621000014 The citation records this snapshot. The page link may show a newer release later.	−USD 49.5 million Exact value Exact value: -49500000 USD 2018-01-01 – 2018-12-31: -49500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2018-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: -49500000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49500000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/halo-20201231.htm#1098553 Filing: 000115903621000014 The citation records this snapshot. The page link may show a newer release later.	USD 4.66 million Exact value Exact value: 4663000 USD 2018-01-01 – 2018-12-31: 4663000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2018-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 4663000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4663000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/halo-20201231.htm#1109100 Filing: 000115903621000014 The citation records this snapshot. The page link may show a newer release later.	−USD 54.16 million Calculation and evidence -49500000 − 4663000 USD Exact free cash flow: -54163000 USD 2018-01-01 – 2018-12-31: -49500000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 4663000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2018-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: -54163000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49500000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/halo-20201231.htm#1098553 Filing: 000115903621000014 Input fundies:CapitalExpenditure: 4663000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/halo-20201231.htm#1109100 Filing: 000115903621000014 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 72.24 million Exact value Exact value: -72240000 USD 2019-01-01 – 2019-12-31: -72240000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2019-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: -72240000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72240000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/halo-20211231.htm#2084793 Filing: 000115903622000014 The citation records this snapshot. The page link may show a newer release later.	−USD 85.42 million Exact value Exact value: -85423000 USD 2019-01-01 – 2019-12-31: -85423000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2019-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: -85423000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -85423000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/halo-20211231.htm#1068473 Filing: 000115903622000014 The citation records this snapshot. The page link may show a newer release later.	USD 4.04 million Exact value Exact value: 4040000 USD 2019-01-01 – 2019-12-31: 4040000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2019-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 4040000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4040000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/halo-20211231.htm#1079083 Filing: 000115903622000014 The citation records this snapshot. The page link may show a newer release later.	−USD 89.46 million Calculation and evidence -85423000 − 4040000 USD Exact free cash flow: -89463000 USD 2019-01-01 – 2019-12-31: -85423000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 4040000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2019-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: -89463000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -85423000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/halo-20211231.htm#1068473 Filing: 000115903622000014 Input fundies:CapitalExpenditure: 4040000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000014/halo-20211231.htm#1079083 Filing: 000115903622000014 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 129.09 million Exact value Exact value: 129085000 USD 2020-01-01 – 2020-12-31: 129085000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2020-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 129085000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 129085000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000012/halo-20221231.htm#2440210 Filing: 000115903623000012 The citation records this snapshot. The page link may show a newer release later.	USD 55.45 million Exact value Exact value: 55454000 USD 2020-01-01 – 2020-12-31: 55454000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2020-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 55454000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 55454000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000012/halo-20221231.htm#1203841 Filing: 000115903623000012 The citation records this snapshot. The page link may show a newer release later.	USD 2.5 million Exact value Exact value: 2504000 USD 2020-01-01 – 2020-12-31: 2504000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2020-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 2504000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2504000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000012/halo-20221231.htm#1217734 Filing: 000115903623000012 The citation records this snapshot. The page link may show a newer release later.	USD 52.95 million Calculation and evidence 55454000 − 2504000 USD Exact free cash flow: 52950000 USD 2020-01-01 – 2020-12-31: 55454000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2504000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2020-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 52950000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 55454000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000012/halo-20221231.htm#1203841 Filing: 000115903623000012 Input fundies:CapitalExpenditure: 2504000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000012/halo-20221231.htm#1217734 Filing: 000115903623000012 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 402.71 million Exact value Exact value: 402710000 USD 2021-01-01 – 2021-12-31: 402710000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2021-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 402710000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 402710000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000008/halo-20231231.htm#2029101 Filing: 000115903624000008 The citation records this snapshot. The page link may show a newer release later.	USD 299.44 million Exact value Exact value: 299440000 USD 2021-01-01 – 2021-12-31: 299440000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2021-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 299440000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 299440000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000008/halo-20231231.htm#1118624 Filing: 000115903624000008 The citation records this snapshot. The page link may show a newer release later.	USD 1.46 million Exact value Exact value: 1457000 USD 2021-01-01 – 2021-12-31: 1457000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2021-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 1457000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1457000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000008/halo-20231231.htm#1127810 Filing: 000115903624000008 The citation records this snapshot. The page link may show a newer release later.	USD 297.98 million Calculation and evidence 299440000 − 1457000 USD Exact free cash flow: 297983000 USD 2021-01-01 – 2021-12-31: 299440000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1457000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2021-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 297983000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 299440000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000008/halo-20231231.htm#1118624 Filing: 000115903624000008 Input fundies:CapitalExpenditure: 1457000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000008/halo-20231231.htm#1127810 Filing: 000115903624000008 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 202.13 million Exact value Exact value: 202129000 USD 2022-01-01 – 2022-12-31: 202129000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2022-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 202129000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 202129000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm#2054061 Filing: 000115903625000010 The citation records this snapshot. The page link may show a newer release later.	USD 240.11 million Exact value Exact value: 240110000 USD 2022-01-01 – 2022-12-31: 240110000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2022-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 240110000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 240110000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm#1161957 Filing: 000115903625000010 The citation records this snapshot. The page link may show a newer release later.	USD 4.81 million Exact value Exact value: 4810000 USD 2022-01-01 – 2022-12-31: 4810000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2022-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 4810000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4810000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm#1171144 Filing: 000115903625000010 The citation records this snapshot. The page link may show a newer release later.	USD 235.3 million Calculation and evidence 240110000 − 4810000 USD Exact free cash flow: 235300000 USD 2022-01-01 – 2022-12-31: 240110000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4810000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2022-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 235300000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 240110000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm#1161957 Filing: 000115903625000010 Input fundies:CapitalExpenditure: 4810000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm#1171144 Filing: 000115903625000010 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 281.59 million Exact value Exact value: 281594000 USD 2023-01-01 – 2023-12-31: 281594000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2023-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 281594000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 281594000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#2267629 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 388.57 million Exact value Exact value: 388571000 USD 2023-01-01 – 2023-12-31: 388571000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2023-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 388571000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 388571000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1274011 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 15.29 million Exact value Exact value: 15294000 USD 2023-01-01 – 2023-12-31: 15294000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2023-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 15294000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15294000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1285310 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 373.28 million Calculation and evidence 388571000 − 15294000 USD Exact free cash flow: 373277000 USD 2023-01-01 – 2023-12-31: 388571000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 15294000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2023-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 373277000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 388571000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1274011 Filing: 000115903626000024 Input fundies:CapitalExpenditure: 15294000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1285310 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	USD 444.09 million Exact value Exact value: 444091000 USD 2024-01-01 – 2024-12-31: 444091000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2024-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 444091000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: 444091000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#2266958 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 479.06 million Exact value Exact value: 479064000 USD 2024-01-01 – 2024-12-31: 479064000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2024-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 479064000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 479064000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1273357 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 10.7 million Exact value Exact value: 10696000 USD 2024-01-01 – 2024-12-31: 10696000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2024-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 10696000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10696000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284719 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 468.37 million Calculation and evidence 479064000 − 10696000 USD Exact free cash flow: 468368000 USD 2024-01-01 – 2024-12-31: 479064000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 10696000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2024-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 468368000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 479064000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1273357 Filing: 000115903626000024 Input fundies:CapitalExpenditure: 10696000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284719 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 316.89 million Exact value Exact value: 316889000 USD 2025-01-01 – 2025-12-31: 316889000 USD Inspect Net Income Open source Share or cite Citation for Net Income · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Net Income: 316889000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 316889000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#2266288 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 651.56 million Exact value Exact value: 651558000 USD 2025-01-01 – 2025-12-31: 651558000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Operating Cash Flow: 651558000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 651558000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1272704 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 6.97 million Exact value Exact value: 6970000 USD 2025-01-01 – 2025-12-31: 6970000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Capital Expenditure: 6970000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6970000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284130 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.	USD 644.59 million Calculation and evidence 651558000 − 6970000 USD Exact free cash flow: 644588000 USD 2025-01-01 – 2025-12-31: 651558000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 6970000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · HALOZYME THERAPEUTICS, INC. · 2025-12-31 HALOZYME THERAPEUTICS, INC. (edgar:1159036) Free cash flow: 644588000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:27:25Z Snapshot: 2db204a73c30e9bc62cab6e68272795552a69819f888a62d139c62e3818295c0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1159036?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 651558000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1272704 Filing: 000115903626000024 Input fundies:CapitalExpenditure: 6970000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm#1284130 Filing: 000115903626000024 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

146 filings · 5,015 latest values · 5,015 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001159036, 1159036, HALO, edgar:1159036

Also known as GLOBAL YACHT SERVICES INC, HALOZYME THERAPEUTICS INC, HALOZYME THERAPEUTICS INC., HALOZYME THERAPEUTICS, INC.

HALOZYME THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation